Physician profile
Sajjad Ali
NPI 1851742092
$1,393.83
in general payments reported to CMS, 2019-2025
13 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.91 · 2020: $30.13 · 2021: $311 · 2022: $465 · 2023: $283 · 2024: $79.09 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $265.31 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $242.34 | 2020-2023 | Camzyos |
| Cumberland Pharmaceuticals, INC. | $161.20 | 2022-2023 | Caldolor |
| Curonix LLC | $137.25 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Novartis Pharmaceuticals Corporation | $130.88 | 2022-2024 | |
| Recor Medical INC | $129.91 | 2025 | Paradise Ultrasound Renal Denervation System |
| Janssen Pharmaceuticals, INC | $100.55 | 2022-2024 | Xarelto |
| Portola Pharmaceuticals, LLC | $72.91 | 2019 | |
| Pfizer INC. | $63.23 | 2022 | |
| Merck Sharp & Dohme LLC | $31.77 | 2022 | |
| Gilead Sciences, INC. | $23.01 | 2024 | Veklury |
| Kestra Medical Technology Services, INC. | $22.37 | 2025 | Assure Wcd |
| Daiichi Sankyo INC. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajjad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.